香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 四川科倫博泰生物醫藥股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6990） 持續關連交易 2026年研發相關 物 資 框架協議 茲提述本公司日期為2023年6月29日 之 招 股 章 程，內 容 有 關2023年研發 相 關 藥 物 及 消 耗 品 框 架 協 議，該 協 議 已 於2025年12月31日 屆 滿。 華 潤 科 倫 為 本 公 司 董 事 劉 思 川 先 生 的 聯 繫 人。因 此，根 據 上 市 規 則 第 十 四A章，華 潤 科 倫 為 本 公 司 的 關 連 人 士。因 此，根 據 上 市 規 則 第 十 四 A章，2026年研發相關 物 資 框架協 ...

Summary of Sichuan Kelun-Biotech Biopharmaceutical FY Conference Company Overview - **Company Name**: Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) - **Industry**: Biopharmaceuticals - **Focus Areas**: Research, development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas [2][3] Key Points Pipeline and Product Development - **Pipeline Programs**: Over 30 pipeline programs, including four approved products with seven indications, two products at NDA stage, and over 10 in clinical development [3] - **Employee Count**: Approximately 2,000 employees, with 900 in R&D, 500 in manufacturing and quality control, and 500 in sales and marketing [3] - **Approved Products**: - TROP2 ADC (SAC-TMT) approved for three indications in China, including lung cancer [4] - HER2-ADC (trastuzumab botidotecan) approved for HER2-positive breast cancer [4] - Cetuximab N01 for RAS wild-type colorectal cancer and PD-L1 for nasopharyngeal carcinoma [4] Clinical Studies and Results - **Clinical Trials**: Five pivotal studies initiated for breast cancer, six for lung cancer, and one for gastrointestinal cancer [5] - **Study Presentations**: Clinical data presented at major conferences, including ESMO and published in journals like the New England Journal of Medicine [6] - **Efficacy Data**: SAC-TMT demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in various cancer types [10] Strategic Collaborations - **Partnerships**: Collaborations with MSD, Ellipses Pharma, and others to enhance pipeline value and global market reach [7][8] - **Out-License Agreements**: Entered into agreements to develop and commercialize novel oncology therapies [8] Market Position and Future Plans - **Market Access**: Three core products included in the National Reimbursement Drug List (NRDL) effective January 2026 [7] - **Commercialization Strategy**: Full-fledged commercialization team established, focusing on Class III hospitals and key opinion leaders [6] - **Growth Plans**: Focus on advancing differentiated pipeline programs, optimizing ADC platform, and expanding capabilities for drug development and commercialization [15][16] Innovation and Technology - **OptiDC Platform**: A world-class drug-conjugate technology platform aimed at optimizing drug design for better efficacy and safety [2][13] - **Non-Oncology Applications**: Exploring ADCs for autoimmune and metabolic diseases, combining biologicals and small molecules [14][15] Additional Insights - **Market Trends**: The company is positioned to leverage its innovative drug development capabilities in a rapidly evolving biopharmaceutical landscape, particularly in oncology [2][15] - **Regulatory Environment**: The inclusion of products in the NRDL indicates a supportive regulatory environment for biopharmaceuticals in China [7] This summary encapsulates the key aspects of the conference, highlighting the company's strategic direction, product pipeline, and market positioning within the biopharmaceutical industry.

第44届摩根大通医疗健康年会持续至今日，期间涌现多项行业动态。英伟达与礼来宣布将在未来五年内 投入10亿美元，于旧金山湾区建设联合研究实验室，加速人工智能在制药行业的应用，双方工程师与医 学专家将协同构建AI模型推动新药研发。荣昌生物与艾伯维就新型靶向PD-1/VEGF双特异性抗体药物 RC148达成独家授权许可协议，艾伯维获得大中华区以外地区的相关开发、生产和商业化权利，荣昌生 物将获得首付款及相关里程碑付款与特许权使用费。约24家国内创新药企在会议上展示临床数据，主会 场演讲企业包含药明康德、药明生物等CXO公司以及百济神州等创新药企，另有17家企业参与亚太专 场。传奇生物在会上公布近期业务进展，其CARVYKTI累计治疗患者数已突破10000例，Raritan生产基 地扩建完成后成为美国规模最大的细胞疗法生产设施，公司预计2026年实现整体盈利。科伦博泰总裁兼 首席执行官葛均友博士在会上分享公司业务最新进展与创新战略。于保法教授携团队参会，展示肿瘤治 疗领域的缓释库疗法，引发广泛关注并初步建立国际合作意向。 药明康德：主营业务为覆盖药物研发生产全流程的CXO一体化服务，于年会上作为主会场演讲企业， 20 ...

Core Viewpoint - The article discusses the evolving landscape of the Chinese healthcare sector, particularly in the context of the upcoming JP Morgan Healthcare Conference, highlighting the diversification of Chinese companies and their strategic positioning in the global market [4][29]. Group 1: Conference Overview - The JP Morgan Healthcare Conference is the largest and most informative international healthcare investment and business development meeting, scheduled for January 12-15, 2026, in San Francisco [4]. - Approximately 22 Chinese companies are participating, categorized into four distinct roles: transaction-oriented innovative drug companies, disclosure companies at commercialization or regulatory milestones, supply-side platforms for global R&D and production outsourcing, and device companies focusing on efficiency and international expansion [4]. Group 2: Supply-Side Platforms - Supply-side platform companies are becoming essential in the global innovation chain, as they focus on delivering stable and efficient R&D and production capabilities, especially during periods of increased volatility in innovative drug companies [6][8]. - WuXi Biologics is shifting its focus from project quantity to project quality, emphasizing capacity utilization and long-term contract stability as key indicators of its value in the global biopharmaceutical supply chain [8]. Group 3: Cross-Border Licensing and Outbound Companies - The pricing logic for Chinese innovative drugs in cross-border licensing has evolved, with a focus on the overall deliverable capabilities rather than just the individual molecules [14]. - Companies like Kelun-Blotech and BaiLi Tianheng are exemplifying this trend by integrating their platforms into global R&D systems and establishing long-term collaborations with multinational pharmaceutical companies [16][18]. Group 4: Regulatory and Commercialization Companies - Companies that have accumulated clinical data and registration progress are transitioning towards verifiable sales and profit curves, shifting their valuation logic from future expectations to tangible cash flows [19]. - Zai Lab and Antengene are in the early commercialization stages, with their success hinging on their products' acceptance in clinical settings and the speed of prescription growth [21][23]. Group 5: Medical Device Companies - Mindray Medical is recognized for its comprehensive coverage of hospital workflows, with a focus on multi-product synergy rather than single-device performance, which is crucial for establishing long-term customer relationships [26]. - MicroPort Scientific is navigating a challenging environment where operational efficiency and cash flow management are critical for sustaining long-term clinical validation and international expansion [28]. Group 6: Industry Trends and Insights - The Chinese healthcare sector is transitioning from a phase of visibility to one of selection, where companies must clearly define their positions and deliverables in a high-intensity global exchange [29]. - The differentiation among Chinese companies in the global system is accelerating, with a clear divide between transaction-oriented innovative drug companies and those that have crossed critical regulatory milestones, focusing on verifiable growth [31].

企业名称科伦博泰生物医药（上海）有限公司法定代表人丁南超注册资本500万人民币国标行业科学研 究和技术服务业>研究和试验发展>工程和技术研究和试验发展地址上海市浦东新区芙蓉花路500弄2号 楼1-2层企业类型有限责任公司（自然人投资或控股的法人独资）营业期限2026-1-12至无固定期限登记 机关浦东新区市场监管局 来源：市场资讯 天眼查显示，近日，科伦博泰生物医药（上海）有限公司成立，法定代表人为丁南超，注册资本500万 人民币，由四川科伦博泰生物医药股份有限公司全资持股。 序号股东名称持股比例1四川科伦博泰生物医药股份有限公司100% 经营范围含医学研究和试验发展（除人体干细胞、基因诊断与治疗技术开发和应用）；货物进出口；技 术进出口。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）自主展示（特色）项目： 技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；组织文化艺术交流活动；会议及展 览服务（出国办展须经相关部门审批）；市场营销策划；企业管理咨询；信息技术咨询服务；信息咨询 服务（不含许可类信息咨询服务）。 ...

Core Viewpoint - Enhertu (DS-8201) has evolved into a "complete entity" with the recent approval for first-line therapy in HER2+ breast cancer, marking significant progress from its initial approval as a third-line therapy in December 2019 to its current status [1][2] Group 1: Enhertu's Progression - Enhertu's journey includes approvals for HER2+ breast cancer in third-line therapy (December 2019), second-line therapy (January 2021), and now first-line therapy [2] - The first-line therapy approval is in combination with pertuzumab, with expectations for single-agent approval in the future [2] Group 2: Competitive Landscape - The HER2 ADC breast cancer market is approaching a critical phase, with companies like Rongchang Biopharma, Kelun-Biotech, and BaiLi Tianheng adopting various strategies to compete [3][6] - Rongchang Biopharma has focused on differentiated strategies, avoiding direct competition in breast cancer and targeting unmet clinical needs in other indications like gastric cancer [4][6] - Kelun-Biotech has actively pursued HER2+ breast cancer, achieving approval for its product A166 as the first domestic ADC for second-line therapy, leveraging a strategy of gradual advancement [7][9] Group 3: Strategic Approaches - BaiLi Tianheng aims to create a competitive product against Enhertu, with its T-Bren ADC targeting both HER2+ breast cancer and non-small cell lung cancer (NSCLC) [11][14] - HengRui Medicine adopts a multi-cancer strategy, focusing on various indications beyond breast cancer, with its SHR-A1811 ADC already approved for HER2-mutated NSCLC [16][17] Group 4: Differentiated Strategies - Lepu Biopharma's strategy centers on combining its ADC with PD-1 therapies, positioning its products as complementary rather than direct competitors [18][20] - In contrast, YingEn Biopharma has established a global strategy, securing a partnership with BioNTech for its DB-1303 ADC, focusing on unmet needs in endometrial cancer [22][24] Group 5: Future Outlook - The competitive landscape in the HER2 ADC market is intensifying, with companies employing diverse strategies to carve out their niches [26] - The future success in this sector may hinge on the depth of differentiated strategies and the ability to commercialize effectively, rather than solely on product efficacy [26]

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Group 1: Overseas Social Services - The investment rating for the overseas social services sector is positive, with a focus on Macau's gaming revenue maintaining double-digit growth and record visitor numbers during New Year's [1][4]. - In December, Macau's gross gaming revenue reached 20.9 billion MOP, representing a year-on-year increase of 14.8%, and recovering to 91% compared to the same period in 2019. The total gross gaming revenue is expected to grow by 9.1% in 2025 [4]. - The total number of visitors to Macau in 2025 is projected to be 40.06 million, a year-on-year increase of 14.7%, marking a historical high. On New Year's Day 2026, the number of visitors reached 188,000, the highest ever for that day [4]. Group 2: Overseas Pharmaceuticals - The investment rating for the overseas pharmaceuticals sector is also positive, with significant developments in drug approvals and clinical trials [2][7]. - BeiGene's BCL2 inhibitor received conditional approval in China for treating chronic lymphocytic leukemia and mantle cell lymphoma, marking it as the first and only BCL2 inhibitor approved for MCL in the country [8][9]. - The Hang Seng Healthcare Index rose by 11.15%, outperforming the Hang Seng Index by 9.12 percentage points, indicating strong market performance [7]. Group 3: Overseas Education - The investment rating for the overseas education sector is favorable, with a focus on vocational education and training [3][14]. - The education index increased by 2.7%, outperforming the Hang Seng Index by 1.3 percentage points, indicating a positive market trend [14]. - The report suggests focusing on Hong Kong vocational education companies, particularly China Oriental Education, which is expected to see enrollment growth due to strategic adjustments in response to market demand [16].

来源：龙谈价值2023 大家好，我是龙哥。 2025年的创新药大行情，总体围绕创新药海外BD交易展开，市场对BD交易的预期从一个极端走向另一 个极端——从已经BD出去的要看到比较明确的临床推进才愿意给部分估值，到大多创新药公司的管线 都被拉出来用放大镜看一圈、只要有潜力BD出去的就炒一把。经过自10月份以来的多个BD交易落地或 海外资产被并购后反而股价暴跌的市场表现，3个月的行情、情绪、关注度的退潮，很多A股和H股的小 公司股价腰斩，市场情绪趋于理性，创新药行业2026年的驱动逻辑被市场重新理解和认知。 2026年行业靠什么驱动？我们此前文章已经多次讲过，淡化一过性的BD交易，后续要靠实实在在的海 外临床推进、海外商业化确定性的提升来驱动，到现在市场对该认知已经逐渐理解，创新药行业β也再 次显现，行业龙头和优质二线公司以及此前讲过的持仓比较纯粹的520880港股通创新药ETF都陆续企稳 向上。 本文我们来讨论一下2026年海外注册临床会有明确进展的公司，所谓的进展既包括新开全球多中心注册 临床，也包括临床数据的读出，我们在此抛砖引玉的列举一部分公司，也欢迎大家的补充。 1、行业影响巨大的两个肿瘤药 首先我们要 ...

智通财经APP讯，科伦博泰生物-B(06990)发布公告，内容有关据中国银行结构性存款协议II认购本金额 为人民币9.8亿元的中国银行结构性存款II。公司已于2026年1月7日终止该认购。由于此终止是在中国银 行结构性存款协议II规定的投资冷静期内执行，本司无需就该认购支付任何款项，且不会因本次终止而 产生任何其他费用或罚款。终止该认购乃经公司进一步考量后，对其理财策略作出调整所致。 ...